^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Signal-C®

    Company:
    Universal DX
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    3ms
    A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation (clinicaltrials.gov)
    P=N/A; Not yet recruiting --> Recruiting | Initiation date: Oct 2023 --> Jan 2024
    Enrollment open • Trial initiation date
    |
    Signal-C®
    6ms
    Universal DX Announces Strategic Collaboration with Quest Diagnostics to Bring Advanced Colorectal Cancer Screening Blood Test to Patients and Providers in the United States (PRNewswire)
    "Universal DX...announced a strategic collaboration with Quest Diagnostics ('Quest')...designed to improve colorectal cancer screening in the United States – for which more than 110 million people may be eligible. Under the commercial agreement between UDX and Quest, Quest plans to perform and provide clinical laboratory services to providers and patients in the United States based on UDX's Signal-C, an advanced colorectal cancer screening blood test, assuming premarket approval of the test in the United States."
    Licensing / partnership
    |
    Signal-C®